Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel, by snatching up Celgene’s Otezla for $13.4 billion.
https://www.fiercepharma.com/pharma/amgen-maker-enbrel-to-pick-up-celgene-s-otezla-for-13-4b-will-ftc-hit-back
FiercePharma
This site is not involved in the creation of this post.
